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ABSTRACT 
Aims: This study aims to assess the diagnostic agreement of lymphovascular 
invasion (LVI) in invasive breast cancer (BC). 
Methods: Data on LVI were collected from the UK NHSBSP pathology external 
quality assurance (EQA) scheme database. 101 BCs assessed over 10-year period 
(2004-2014) were included. Cases were scored by an average of 600 pathologists. 
Three H&E stained slides from each case were reviewed by 3 pathologists and 
additional variables were evaluated.  
Results: In the whole series, the overall kappa value was 0.4 (range 0.26 to 0.53). 
On review, LVI was detected in all 3 slides in 20 cases (20%), in 2 slides in 12 cases 
and in 1 of the 3 slides in 9 cases and was not seen in 60 cases. For concordance 
analysis, the first and last groups were used to represent cases with definite (LVI+) 
and absent LVI (LVI-) respectively.  In the LVI+ group (n=20), the level of agreement 
ranged from 0.54 to 0.99 (median 0.86). In the LVI- group (n=60) the level of 
agreement ranged from 0.52 to 1.00 (median 0.93), with 44% of cases showing inter-
observer concordance of >95%. There was a correlation between increasing number 
of involved lymphovascular spaces in the section and higher LVI reporting 
concordance. Some degree of retraction/fixation artefacts was observed in 35% of 
cases; this was associated with a lower concordance rate. Conclusions: The 
concordance of reporting LVI is variable. Cases without LVI and those with multiple 
involved vessels are likely to have the highest concordance and the highest 
detection rates.  
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INTRODUCTION 
Lymphovascular invasion (LVI), defined by the presence of tumour cells within 
lymphovascular spaces, in breast cancer (BC) is identified morphologically by 
microscopic examination of the primary tumour, with or without endothelial specific 
markers.  LVI is considered as a marker of metastatic potential and its prognostic 
value has been demonstrated by several independent studies (1-9). In a previous 
study of the Nottingham series (n=3812 cases) diagnosed by any of 4 pathologists in 
routine practice over 15-year period (2), we demonstrated that LVI is not only an 
independent prognostic variable in the whole series, and in the various prognostic 
subgroups, but also provides a risk equivalent to that provided by one higher stage 
category (e.g. pT1 to pT2) or from metastatic tumour in one or two lymph nodes 
compared to lymph node negative disease (2). Despite this, there remain concerns 
regarding its inclusion in staging systems (10) and in prognostic risk assessment 
tools (11, 12). This mainly stems from one or more of the following factors: 1) 
Variation in the frequency of LVI in the different studies. Although this is often 
perceived as a reflection of inconsistency of its detection among pathologists, this 
variation may be related to inherent differences in the study cohorts; for example, the 
range of LVI varies from 12% in grade 1 and small size tumours to 69% in tumours 
with high nodal stage in the same cohort (2).  2) The difficulty and subjectivity in 
identifying morphologically subtle LVI or considering intratumoural LVI (13). Although 
it is reported that immunohistochemistry (IHC) can assist in the identification of up to 
20% of morphologically undetectable LVI on haematoxylin and eosin (H&E) stained 
sections, this does not seem to increase its prognostic significance (2). Most of these 
cases and those that are reported as “probable LVI” on H&E stained sections show 
an outcome intermediate between the positive and negative groups, akin to the 
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intermediate risk category of multigene prognostic assays (2, 14). 3). Being excluded 
from guideline recommendations and for practical reasons, IHC is not routinely used 
to assess LVI in most centres due to the perceived low reproducibility of identification 
of LVI (15). In a previous concordance study of 295 breast cancers included in the 
UK National Health Service Breast Screening Programme (NHSBSP) pathology 
interpretive external quality assurance (EQA) scheme, agreement in the assessment 
of LVI ranged from fair to moderate, with an overall kappa value of 0.4 (16). 
However, due to the microfocal nature of LVI and the limitation of the scheme 
methodology, we hypothesised that these figures were not representative of the 
actual concordance levels of LVI in BC. As the level of diagnostic concordance of 
any prognostic variable is important in determining its clinical utility, the present 
study aims to investigate further the diagnostic agreement of LVI in BC in detail, and 
to evaluate the reasons underlying the apparent low interobserver agreement, in an 
attempt to improve its clinical validity.    
 
MATERIALS AND METHODS 
Study cohort 
This study is based on data obtained from the NHSBSP breast pathology EQA over 
a 10 year period (2005-2014). Description and details of the standard operating 
procedures have been published previously (15, 17, 18). In brief, over 65 sets 
(approximately 1 set per 10 participants) of 12 cases are circulated twice a year 
(over a three month period) to pathologists who report breast pathology in the UK 
(consultant pathologists with FRCPath or an equivalent degree with no restriction 
based on experience or number of breast specimens reported). Each case 
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comprises one freshly prepared haematoxylin and eosin (H&E) stained slide from a 
representative tumour tissue block of therapeutically surgically excised specimens 
(no biopsy material was included). No clinical details or immunohistochemistry 
results are provided. The cases are submitted by participants for use in the scheme. 
The slides are checked at the coordinating centre and reviewed by the organiser 
following preparation of the sections. Cases are then eliminated if section quality is 
too poor to interpret the histological appearances adequately, or if the key lesion is 
not adequately represented in all the sections cut. LVI is not a criterion for inclusion 
or exclusion of cases. A standard reporting form is completed by each participant for 
each case and this includes diagnostic classification of the lesion. For cancer cases, 
this includes the minimum standard data set information, as required by the UK 
NHSBSP and by the Royal College of Pathologists (19-21) 
(http://www.rcpath.org/publications-media), which includes LVI as one item. In the 
scheme, LVI is presently reported as present or absent with no probable/possible 
category. The scheme includes an average of 650 participants (range 602 to 749). 
The participating pathologist independently examines the slides and, for each case, 
completes a tick box proforma, now an online electronic process 
(http://www.nccbp.com/).  
The level of agreement was assessed using κ statistics, as previously described (15, 
22, 23). Values of κ range from 0 for chance agreement only to +1 for perfect 
agreement, with a negative value implying systematic disagreement. The range of κ 
is interpreted as follows: 0–0.20 = slight agreement; 0.21–0.40 = fair; 0.41–0.60 = 
moderate; 0.61–0.80 = substantial; and 0.81–1.00 = almost perfect agreement.  
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Histological review and analysis 
During the time period of this study 120 invasive carcinoma cases were included in 
the scheme.  The present analysis includes 101 BCs with LVI data recorded and 
available and where 3 H&E sections were available for review. Cases with 
incomplete data or missing slides were excluded (n=19). From each case, 3 H&E 
freshly stained slides (first, middle and last levels of average 70 sections from each 
tumour block) were reviewed by three pathologists (PP, AA and ER). The following 
features were scored: 1- number of slides showing definite LVI agreed by the 
reviewing pathologists. 2- number of involved lymphovascular spaces per case, 
counted as the number of images of LVI regardless of the likely number of vessels 
involved (i.e. tangential cut vessels; Figure 1). This has been scored as 0, 1, 2, 3, 4, 
5 or more than 5.  The number of foci of LVI was counted in the 3 slides and the 
highest number was recorded. 3- size of the largest intravascular tumour embolus. 4- 
location of LVI (peritumoural or away from the main tumour mass) and the distance 
from the tumour in mm. 5- presence of groups of tumour cells in spaces around the 
main tumour mass. 6- presence of erythrocytes and/or thrombus. 7- presence of 
adjacent lymphovascular channels of varying sizes. 8- presence of adjacent thick 
wall vessels. 9- presence and degree of shrinkage artefact on each slide. 10- 
presence and number of foci suspicious of LVI. 11- presence of DCIS. Foci that were 
considered not definite LVI were classified as negative following discussion between 
the three scorers. No immunohistochemical markers were assessed in this study.  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RESULTS 
This study included 101 BC that had been assessed by an average of 600 
pathologists (range 477 to 672). LVI involvement was observed in all 3 slides in 20 
cases, in 2 slides in 12, in 1 of the 3 slides in 9 cases and in none of the 3 in 60 
cases (Table 1). Cases with LVI seen in all 3 slides were considered as showing 
definite LVI (LVI+) (n=20) whereas cases with no LVI in any of the 3 slides examined 
were considered as LVI negative (LVI-) (n=60). These 2 categories only (LVI+ and 
LVI-) were used to analyse concordance. Cases with LVI seen in only 1 or 2 of the 3 
slides were excluded from the concordance analysis as it was considered more likely 
in this situation that some participants received levels for assessment where LVI was 
genuinely not present. Analysis of these cases with microfocal LVI may therefore not 
truly reflect agreement in assessment. Conversely, if LVI was present in all 3 levels 
examined, it was considered more likely that it was present in the sections in 
between (although not invariably the case) and these were included in the 
concordance investigation. Overall, the concordance rate of reporting LVI was >95% 
in 26 (25%) cases. Concordance between 75% and 95% was identified in 50 cases 
(50% of the total). The highest concordance rates were seen in the LVI- group, with 
44% of cases having concordance of >95%. In the LVI- group, the 3 cases which 
showed concordance rates <65% featured significant retraction artefact throughout 
the tumour, making interpretation difficult (Figure 2).  
In the LVI+ group, 86% of the participants (7814/9087 of the overall scores) 
diagnosed these 20 cases as LVI positive. On review, the 2 cases with concordance 
<65% showed that one of the 3 slides contained one (in one case) or two (in the 
other case) tiny foci of LVI only, which may indicate that some slides in between may 
be missing LVI.   
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There was a correlation between higher concordance rates and increasing number 
of involved vessels (p=0.001). The number of involved vessels varied from 1 (10%) 
to ≥6 images (40%). No statistical association was identified between of LVI 
concordance rates and size of the involved vessels, distance of the vessels from the 
tumour, presence of fibrous tracts, dilated vessels, or red blood cells or thrombosis 
within the involved vessels (p>0.05).  
There was an association between histological grade of the tumour and reporting of 
LVI in both the LVI- and LVI+ subgroups.  In the LVI- group, grade was inversely 
associated with LVI classification; in grade 1 tumours 94% of participants reported 
an absence of LVI compared to 90% in grade 2 and 82% in grade 3 tumours 
(p=0.011). In the LVI+ group, grade was positively associated with rates of reporting 
of LVI; the detection rate was 92% in grade 3 tumours compared to 78% in grade 2 
cancers (p=0.039). 
Certain histological tumour types showed high levels of concordance including 
tubular (100%), medullary (99%), adenoid cystic (96%), and classical lobular (95%) 
carcinomas. Three cases of invasive micropapillary carcinomas were included in this 
study and all showed LVI with a mean concordance rate of 91%. Other types 
showed lower concordance rates, including pleomorphic lobular carcinoma (65%), 
invasive papillary (68%) and a single case of glycogen rich carcinoma (64%). 
Mucinous and ductal NST lesions showed 85% and 81% concordance rates 
respectively.  
Some degree of retraction/fixation artefacts was observed in 35% of cases, including 
the LVI+ (40%) and LVI- (32%) groups but this difference was not significant 
(p=0.587). Also no association between retraction artefacts and the presence of LVI 
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in the 1, 2 or 3 slides from each case was found.  However, there was a correlation 
between the presence of retraction artefacts and lower concordance rates of 
reporting LVI in the whole cohort (p=0.009), and in the LVI- subgroup in which the 
mean concordance rate declined from 91% to 78% (p<0.001). In the LVI+ group the 
rate of reporting LVI increased from 79% to 89% when retraction artefacts were 
present but the difference was not significant (p=0.115). 
There was a correlation between the number of involved vessels and the presence 
of LVI in more of the reviewed slides; all cases with ≥4 involved vessels were seen in 
the 20 cases in which LVI was seen in the 3 slides (p=0.044). Similar associations 
were found with the presence of dilated vascular space (p=0.048) and adjacent 
vascular channels of variable size (p=0.034).  
The difference between scheme participants and scheme co-ordinators was 
statistically significant in the LVI+ group in which co-ordinators showed a higher 
detection rate of LVI than participants (p=0.008). No differences between scheme 
participants and co-ordinators was observed in the LVI- group or in the groups 
showing LVI in 1 or 2 of the 3 slides (p>0.05) 
 
DISCUSSION 
In the context of interobserver agreement studies, the UK EQA scheme provides a 
reflection of routine practice to a large extent, and the current study provide the 
largest sample size reported to date in terms of number of participants and invasive 
breast carcinomas. Although LVI is not a scored item of performance appraisal in the 
scheme, the current study indicates high levels of concordance. In a previous study 
of interobserver agreement utilising one slide per case prepared as glass slides 
10 
 
and/or digital images of scanned slides, LVI achieved higher level of concordance 
than histological grade, tubule formation or tumour lymphocytic infiltrate (24).  
Of note, the current study highlights the microfocal nature of LVI and that only 20% 
of cases showed evidence of LVI in all 3 levels, representing a consistent presence 
in the tumour tissue, whilst 21% showed only focal and thus inconsistent LVI foci (i.e. 
seen in some but not all levels). The presence of LVI in some slides but not in others 
may explain the lower interobserver agreement in some studies involving multiple 
tissue levels. However, this study indicates that when there are 4 or more involved 
vessels present the likelihood that LVI will be seen in any section randomly cut from 
the tissue blocks and recognised by the pathologist as ‘positive’ is high. There is 
evidence that patients with tumours with extensive LVI have a shorter survival than 
those with focal, or without, LVI (25). In breast carcinomas with extensive LVI and 
therefore poor prognosis, LVI is likely to be more widely presented, detected in any 
section randomly cut and likely to be reported by the pathologist. Breast carcinomas 
with fewer foci of LVI have a lower chance of being reported as LVI positive, but 
these may not significantly affect the outcome of large cohort studies. This is in 
keeping with the association between LVI and outcome in different studies despite 
the variation in positivity rates in these studies. 
This study emphasises the impact of methodology on the published concordance 
rate of such microfocal lesions. The possibility of different findings in other slides not 
examined in this study (i.e. the slides in between the 3 examined) cannot be 
excluded and this may have a detrimental impact on the concordance rate. Although 
in the LVI positive and negative groups we have found high concordance rates of LVI 
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detection and reporting, using a single slide in the EQA scheme, for instance utilising 
a digital imaging platform, may further improve consistency of LVI reporting.  
This study also demonstrates a relationship between consistency of reporting LVI 
and features of the primary invasive tumour, including histological grade and type. 
Although some tumour types in this study are associated with low concordance 
rates, these tumours are rare; it is likely that the participant pathologists may pay 
more attention to the primary diagnosis of these rare invasive tumours than 
assessing prognostic markers in such EQA schemes. However, in routine practice, 
once an invasive diagnosis is made, we believe it is likely that pathologists will 
assess other prognostic variables, including LVI, more thoroughly.   
In this EQA scheme cases are submitted randomly, being chosen from routine 
practice by participating pathologists. Thirty five % of cases showed some degree of 
retraction/fixation artefacts as assessed by the reviewing pathologists. There was an 
inverse association between the presence of retraction artefacts and concordance of 
LVI reporting; more LVI- tumours were reported as positive in the presence of 
retraction artefact. In the LVI+ group the rate of reporting LVI also increased by 10% 
when retraction artefact was present but no IHC was available to confirm whether 
this increase was related to the presence of artefactual shrinkage or genuine LVI. 
The presence of red blood cells in the involved vessels, number of tumour cells 
within the vessels, and location of the vessels appeared of limited impact on 
consistency of LVI reporting.  
In conclusion, these results demonstrate a high level of consistency of reporting LVI 
in breast cancer. Limitations in the methodology of concordance studies may 
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underestimate performance in routine practice. Education, training and guidance are 
expected to improve consistency, and to maintain the high level of performance. 
 
Take home messages 
-The concordance of reporting lymphovascular invasion in breast cancer is variable.  
-There is a correlation between increasing number of involved lymphovascular 
spaces in the section and higher LVI reporting concordance. 
-Cases without LVI and those with multiple involved vessels are likely to have the 
highest concordance and the highest detection rates. 
-When LVI is present in the slide, the median level of agreement is 0.86 and when it 
is absent the median level of agreement is 0.93. 
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Tables 
Table 1:  Mean, median and range of frequency of reporting (%) LVI in the whole 
series (n=101), LVI positive (n=20) and LVI negative (n=60) cases and those with 
LVI seen only in 1 or 2 of the 3 slides (n=21) by all participants and by the scheme 
co-ordinators. 
 Mean Median Range 
Whole series    
Pathologists 0.83 0.88 0.50-1.00 
Co-ordinators 0.86 0.89 0.50-1.00 
    
LVI definite (in all 
3 slides) 
   
Pathologists 0.83 0.86 0.54-0.99 
Co-ordinators 0.89 0.95 0.63-1.00 
    
LVI negative (in 
all 3 slides) 
   
Pathologists 0.88 0.93 0.52-1.00 
Co-ordinators 0.88 0.90 0.50-1.00 
    
LVI seen in one 
slide 
   
Pathologists 0.73 0.65 0.61-0.95 
Co-ordinators 0.83 0.86 0.65-1.00 
    
LVI seen in two 
slides 
   
Pathologists 0.69 0.65 0.51-0.92 
Co-ordinators 0.73 0.71 0.50-0.95 
 
 
 
Figure legends 
Figure 1: A case of breast cancer showing clear lymphovascular invasion adjacent 
to the invasive tumour and involving vascular space with tangential cutting. In this 
study this was counted as 3 images of lymphovascular invasion. 
Figure 2: A case of breast cancer with retraction artefact making assessment of 
lymphovascular invasion difficult due to similarity to DCIS with shrinkage artefact  
 
